Summary of Suzhou Ribo Life Science (6938.HK) Conference Call Company Overview - **Company**: Suzhou Ribo Life Science - **Ticker**: 6938.HK - **Industry**: siRNA Drug Development Key Points Industry and Market Potential - The global oligonucleotide drug market is projected to grow from **US$5.7 billion in 2024** to **US$54.9 billion by 2034**, with a CAGR of **29.4% from 2024 to 2029** and **21.6% from 2029 to 2034** [28][29] - siRNA drugs are expected to capture a greater market share, outpacing other oligonucleotide modalities [28] Company Strengths - Ribo is a pioneer in siRNA technology with a robust pipeline of **seven in-house discovered drug assets** in clinical trials targeting cardiovascular, metabolic, renal, and liver diseases [12][3] - Proprietary delivery technologies, including **RiboGalSTARTM**, enhance targeting specificity and safety, positioning Ribo as a leader in siRNA therapeutics [25][26] - Collaborations with major pharmaceutical companies, including **Boehringer Ingelheim** and **Madrigal**, with total deal value exceeding **US$6.0 billion** [4][26] Key Products - **RBD4059**: A potential first-in-class FXI-targeting siRNA drug for thrombotic diseases, with estimated peak sales potential of **US$6.8 billion** [2][15] - **RBD5044**: A potential best-in-class APOC3-targeting siRNA for hypertriglyceridemia, showing competitive triglyceride-lowering efficacy [21] - **RBD1016**: A promising siRNA candidate for chronic hepatitis B (CHB) and coronary heart disease (CHD), with favorable safety and efficacy profiles [22][23] Financial Overview - **2023 Net Profit**: -RMB 428 million - **2024 Net Profit**: -RMB 270 million, with an expected EPS growth of **36.9%** [5][9] - **Target Price**: HK$102, representing an expected share price return of **73.5%** [6][11] Clinical Development and Efficacy - RBD4059 has shown a **dose-dependent reduction** in FXI activity, with maximum percentage changes from baseline of **67.5% to 91.6%** across different dosing cohorts [37] - The phase 2a trial for RBD4059 is expected to complete by the end of **2025** [35] Risks and Challenges - Key risks include potential R&D failures, slower-than-expected product launches, competition, and historical lack of profitability [4][11] Conclusion - Suzhou Ribo Life Science is positioned as a leader in the siRNA therapeutic space with significant growth potential driven by innovative products and strategic collaborations. The company faces challenges typical of biotech firms, including the need for successful clinical outcomes and market acceptance.

Investment Rating - The report assigns a "Buy" rating for RiboBio-B (06938) as a first-time coverage [1][7]. Core Insights - RiboBio focuses on the development and industrialization of small nucleic acid drugs, being one of the pioneers in this field. The company has established a fully integrated research and development platform for small nucleic acid drugs, covering various chronic diseases such as cardiovascular, metabolic, kidney, and liver diseases [5][17]. - The small nucleic acid drug industry is entering a period of explosive growth, with a projected compound annual growth rate (CAGR) of 29.4% from 2024 to 2029, driven by advancements in delivery technology and the expansion of indications from rare diseases to chronic diseases [27][28]. - RiboBio's differentiated pipeline includes RBD4059, which targets FXI for thrombotic diseases, RBD5044 for dyslipidemia, and RBD1016 for hepatitis B functional cure, showcasing the company's potential to meet unmet clinical needs [32][46]. Financial Data and Profit Forecast - The company is expected to generate revenues of RMB 143 million in 2024, with a projected growth to RMB 350 million in 2026 and 2027. The net profit attributable to ordinary shareholders is forecasted to be -RMB 270 million in 2024, improving to -RMB 133 million in 2026 [6][8]. - The target price for RiboBio is set at RMB 76.24, equivalent to HKD 86.08, indicating a potential upside of 46% from the market capitalization as of March 4, 2026 [7][8]. Pipeline and Market Opportunities - RiboBio has a robust pipeline with over 20 preclinical drugs and 7 clinical drugs, including 4 in Phase II trials. The core pipeline targets chronic diseases, addressing significant unmet clinical needs [30][31]. - RBD4059 is positioned as the world's first clinical-stage siRNA drug for thrombotic diseases, with a significant market potential as the global anti-thrombotic market is expected to reach USD 59.3 billion by 2024 [32][33]. - RBD5044 aims to address the unmet needs in the dyslipidemia market, which is projected to grow from USD 24 billion in 2019 to USD 35.3 billion by 2029 [46][49]. Key Assumptions and Catalysts - The revenue for 2025-2027 is primarily expected to come from business development (BD) licensing income, with significant milestone payments anticipated from collaborations with partners like Boehringer Ingelheim and Qilu Pharmaceutical [8][9]. - Key clinical data releases for RBD4059, RBD5044, and RBD1016, as well as new licensing agreements with overseas companies, are expected to act as catalysts for stock price performance [10].

Core Insights - The small nucleic acid drug sector is experiencing a significant surge, marking the beginning of a golden era driven by technological breakthroughs and capital enthusiasm [2][11][22] Industry Developments - On January 5, 2026, Sanofi's APOC3 siRNA drug Plozasiran was approved for domestic market use to treat hyperlipidemia [1] - On January 9, 2026, Rebio Biotech, known as "China's first small nucleic acid stock," successfully listed on the Hong Kong Stock Exchange, with its stock price soaring by 40% on the first day, leading to a market capitalization exceeding 13 billion HKD [1] - China National Pharmaceutical Group announced a 1.2 billion CNY acquisition of Hegia Biotech, securing the world's first clinically validated liver-targeted delivery platform capable of annual dosing [1] Market Trends - The global small nucleic acid drug market has seen nearly 100 business development (BD) collaborations in the past three years, with transaction numbers and amounts increasing annually, reaching over 30 BD deals in 2025 totaling nearly 30 billion USD [4][9] - Notable transactions in 2025 included Novartis acquiring Avidity Biosciences for 12 billion USD and multiple other significant deals involving RNA therapies [7][9] Clinical Advancements - Ionis's APOC3 ASO drug Olezarsen showed promising results in reducing triglyceride levels by up to 72% in patients with severe hypertriglyceridemia, leading to an increase in peak annual sales forecast from 1.5 billion USD to 2.5 billion USD [12] - GSK's ASO therapy Bepirovirsen is expected to be the first drug to achieve functional cure for chronic hepatitis B, with a peak annual sales potential of 2 billion USD [12] Emerging Opportunities - The small nucleic acid drugs are expanding into various therapeutic areas, including obesity and kidney diseases, with promising results from clinical trials demonstrating significant weight loss and metabolic health improvements [13][15] - The number of small nucleic acid drugs in development globally has surpassed 1,200, with siRNA and ASO therapies being the most prominent [17] Strategic Collaborations - Domestic companies are increasingly recognized for their innovative value in small nucleic acid drugs, with active BD transactions, including significant collaborations by Rebio Biotech and other firms [18][21] - Companies like Saintin Biotech are forming strategic partnerships with major pharmaceutical firms to advance their small nucleic acid drug pipelines [19] Conclusion - The convergence of technological advancements, capital influx, and successful clinical outcomes is propelling small nucleic acid drugs into a pivotal position within the pharmaceutical industry, with China poised to become a global innovation hub [22]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The pharmaceutical sector underperformed the overall market this week, with a 0.68% decline in the biotechnology sector compared to a 0.03% increase in the overall A-share market [1] - The report highlights the successful listing of Rebio Biotech on the Hong Kong Stock Exchange, focusing on the small RNA industry and its potential [2] - Rebio Biotech has established a proprietary delivery platform, RiboGalSTAR, and has entered into commercialization partnerships valued at over $2 billion [2] - The core asset RBD4059, targeting FXI, is currently in clinical phase 2a studies in Sweden, showing promise in treating thrombotic diseases [2][21] Summary by Sections Market Performance - The overall A-share market increased by 0.03%, while the Shanghai Composite Index decreased by 0.57%. The biotechnology sector saw a decline of 0.68% [1][26] - Within the biotechnology sector, chemical pharmaceuticals fell by 2.40%, while medical services rose by 3.29% [1][26] Company Overview - Rebio Biotech focuses on small RNA drug development, with seven products in clinical research, four of which are in phase 2 trials [2][9] - The company has a strong management team with extensive experience in drug development and production [16][18] Financial Projections - The report provides earnings forecasts for key companies, with Rebio Biotech's core asset RBD4059 showing significant potential in the thrombotic disease market [3][21] - The report recommends investment opportunities in the CXO sector and highlights the clinical progress of innovative drugs overseas [2][36] Valuation Metrics - The TTM P/E ratio for the pharmaceutical and biotechnology sector is 38.70x, compared to 22.18x for the overall A-share market [31] - Specific sub-sectors show varying P/E ratios, with chemical pharmaceuticals at 47.60x and medical services at 36.15x [31]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The pharmaceutical sector underperformed the overall market, with a TTM P/E ratio of 38.70x, which is at the 84.85th percentile of the past five years [1][31] - The report highlights the recent IPO of RiboBio, a leading company in the small RNA drug development sector, which has established a proprietary delivery platform, RiboGalSTAR, focusing on cardiovascular, metabolic, renal, and liver diseases [2][9] - RiboBio has seven products in clinical research, with four advancing to Phase II trials, demonstrating the effectiveness and safety of its delivery system [2][17] Summary by Sections Market Performance - The overall A-share market increased by 0.03%, while the biopharmaceutical sector declined by 0.68%, with chemical pharmaceuticals dropping by 2.40% [1][26] - The report notes significant individual stock movements, with some companies experiencing substantial gains and others facing steep declines [26][30] Company Focus: RiboBio - RiboBio has formed strategic partnerships with Boehringer Ingelheim and Qilu Pharmaceutical, with a total transaction value exceeding $2 billion, validating the platform's value [2][17] - The core asset, RBD4059, is in Phase IIa trials in Sweden for treating thrombotic diseases, showing promising results in reducing thrombus formation without increasing bleeding risk [2][21] - RBD4059's clinical data indicates a significant reduction in FXI activity, with a maximum percentage change of 91.6% at the highest dosage [22] Investment Recommendations - The report suggests focusing on investment opportunities in the CXO sector and the clinical progress of innovative drugs overseas [2] - Specific companies recommended for investment include Mindray Medical, WuXi AppTec, and Aier Eye Hospital, all rated as "Outperform" [3][36]

Core Viewpoint - Suzhou Rebio Biotech (6938.HK) has successfully listed on the Hong Kong Stock Exchange, marking the arrival of the first mRNA concept stock in the market and becoming a significant target for investors looking to enter the mRNA sector [1][3]. Group 1: IPO Details - Rebio's stock surged 42% on its debut, closing at HKD 82.10, with continued growth in the following week [3]. - The company issued 31.6 million shares at HKD 57.97 each, raising approximately HKD 1.7 billion (around USD 218 million) [3]. - The IPO attracted 11 cornerstone investors, including Taikang Life and Da Cheng International Asset Management, who collectively subscribed to 13.4 million shares, accounting for 42.5% of the total offering [3]. - The public offering was oversubscribed more than 100 times, with international investors oversubscribing by over 15 times [3]. Group 2: Product Pipeline and Collaborations - Rebio currently has seven self-developed drug assets in clinical trials targeting cardiovascular, metabolic, renal, and liver diseases [4]. - Among these, RBD4059 is the world's first siRNA drug for treating thrombotic diseases, while RBD5044 is the second siRNA drug in clinical development for treating hypertriglyceridemia [4]. - All products are still in clinical stages, with RBD4059 set to enter phase 2b trials and RBD5044 in phase 2 trials [4]. - Rebio has secured recognition and partnerships with several pharmaceutical companies, leading to significant revenue opportunities, including a collaboration with Qilu Pharmaceutical for the commercialization of RBD7022 and a partnership with Boehringer Ingelheim for innovative nucleic acid therapies, with a total collaboration value of up to USD 2 billion [4]. Group 3: Financial Projections - Rebio's revenue is projected to grow from nearly zero in 2023 to CNY 143 million (approximately USD 20.5 million) in 2024, with expectations to reach CNY 104 million in the first half of 2025 [5]. - The company reported a loss of CNY 97.8 million in the first half of 2025, an improvement compared to a loss of CNY 142 million in the same period of 2024 [5].

Core Viewpoint - The listing of Rebio Biotech (6938.HK) on the Hong Kong Stock Exchange marks a significant milestone for China's small nucleic acid drug development, transitioning from "technical accumulation" to "value realization" [1] Group 1: Market Reaction and Financial Performance - The market reacted positively, with Rebio's stock price rising over 29% in pre-listing trading and closing at 82.1 HKD per share on its first day, reflecting strong investor confidence in Chinese innovative pharmaceuticals [1] - Rebio's financial performance shows a strong revenue growth of 56.57% year-on-year, reaching 1.04 million RMB in the first half of 2025, while losses narrowed by 30.94% during the same period [4][5] - The revenue growth is primarily driven by licensing and collaboration agreements with major players like Boehringer Ingelheim and Qilu Pharmaceutical, indicating recognition of its underlying platform technology [4] Group 2: Strategic Development and R&D - Rebio's platform-based R&D approach is transforming the traditional investment model in biotechnology, moving from betting on single molecules to a modular and scalable development strategy [6] - The company aims to advance 2-4 assets to clinical trials annually, leveraging its platform's efficiency and confidence in its development capabilities [6] - Rebio has established a strong competitive barrier through its intellectual property, holding 255 granted patents and 218 pending applications, alongside a GMP-compliant production facility in Jiangsu [7] Group 3: Ecosystem and Global Strategy - Rebio's strategy combines internal development with external collaboration, targeting global diseases with significant patient populations, such as cardiovascular conditions [9] - The company has formed strategic partnerships, such as with Boehringer Ingelheim, to enhance its technology platform's recognition and optimize commercialization efficiency [11] - Establishing a clinical team in Sweden allows Rebio to conduct high-quality clinical trials independently, enhancing global development efficiency and regulatory communication [12] Group 4: Industry Implications - Rebio's listing signifies a shift in the Chinese biotechnology sector from "following innovation" to "source innovation," showcasing its platform-based R&D capabilities and global operational vision [13] - The company is positioned to accelerate its transition from clinical to commercial stages, with the potential for its platform value and pipeline to resonate in the emerging nucleic acid drug era [13]

Core Viewpoint - Ribo Life Science, a leader in the small nucleic acid pharmaceutical field, successfully listed on the Hong Kong Stock Exchange, achieving a market capitalization exceeding HKD 13 billion, representing over 30 times growth compared to its valuation after the A-round investment by Panlin Capital [1][5]. Company Overview - Ribo Life Science was founded in 2007 and is a pioneer in small nucleic acid (siRNA) drug research and development in China, establishing a comprehensive platform for small nucleic acid drug development [7]. - The company focuses on iterative research and development of small nucleic acid chemical modifications and drug delivery technologies, supporting all stages from early research to commercialization [7]. Product Pipeline - Ribo Life Science has developed a robust product pipeline, including: - RBD4059, a siRNA drug targeting FXI for treating thrombotic diseases, which has completed all subject enrollments in Phase IIa clinical trials [8]. - RBD5044, targeting APOC3 for treating hypertriglyceridemia, has received EU approval for Phase II clinical trials [8]. - RBD7022, targeting PCSK9 for treating hypercholesterolemia, has completed Phase I trials in China and is advancing to Phase II trials [8]. - RBD1016, targeting HBV for chronic hepatitis B treatment, is in Phase II trials and has received orphan drug designation from the EMA [10]. Globalization and Commercialization Strategy - Ribo Life Science integrates local R&D advantages with international expertise, establishing a world-class small nucleic acid drug development system [12]. - The company has multiple R&D centers in Suzhou, Beijing, and Europe, and successfully completed a USD 33 million equity financing for its overseas R&D center in Sweden [12]. Strategic Partnerships - In December 2023, Ribo Life Science entered into a licensing and collaboration agreement with Qilu Pharmaceutical for the development and commercialization of RBD7022 in Greater China, receiving over RMB 700 million in upfront and milestone payments [13]. - The company also signed a collaboration agreement with Boehringer Ingelheim to develop innovative therapies for NASH/MASH using its proprietary RiboGalSTAR™ technology, with a total transaction value exceeding USD 2 billion [13]. Investment Journey - Panlin Capital has been a key investor in Ribo Life Science since its A-round financing in 2015, providing crucial support during challenging times in the small nucleic acid industry [5][14]. - The investment journey includes six rounds of funding, demonstrating a commitment to supporting the company's growth and innovation in the biopharmaceutical sector [14][19].

Core Viewpoint - Suzhou Rebio Technology Co., Ltd. (Rebio) has successfully listed on the Hong Kong Stock Exchange, with its share price closing at HKD 82.10, reflecting a 41.62% increase from the issue price of HKD 57.97 [1][2]. Group 1: Company Overview - Rebio is focused on the research and development of small nucleic acid drugs, particularly specializing in siRNA therapies [1]. - The total number of shares issued in this offering was 31,610,400 H-shares, with 2,748,800 shares allocated for public offering in Hong Kong and 28,861,600 shares for international placement [2]. Group 2: Financial Details - The total proceeds from the offering amounted to HKD 1,832.45 million, with net proceeds of HKD 1,701.80 million after deducting estimated listing expenses of HKD 130.65 million [2][3]. - The funds raised will be allocated to the research and development of core products RBD4059, RBD5044, and RBD1016, as well as to support pipeline assets in preclinical stages and enhance the technology platform [3]. Group 3: Investor Participation - Key cornerstone investors include Arc Avenue Asset Management, Bright Stone Holdings, and several asset management firms, collectively acquiring 42.5% of the offering [6][7]. - The cornerstone investors' total shareholding includes significant contributions from various funds and insurance companies, indicating strong institutional interest in Rebio [6]. Group 4: Financial Performance Projections - For the fiscal years ending December 31, 2023, and December 31, 2024, Rebio is projected to generate revenues of RMB 0.04 million and RMB 142.6 million, respectively, with net losses of RMB 437.3 million and RMB 281.5 million [8]. - The company anticipates a continued trend of net losses in the upcoming periods, with projected losses of RMB 141.6 million for the six months ending June 30, 2025 [8].

Core Viewpoint - Suzhou Ribo BioTechnology Co., Ltd. (Ribo Bio) officially listed on the Hong Kong Stock Exchange, attracting significant investor interest due to its solid technology and clear pipeline in the biotech sector [1] Company Overview - Ribo Bio's global offering consisted of 31.61 million shares at an issue price of HKD 57.97 per share, with the first-day opening price at HKD 75, reflecting a 29.38% increase from the issue price [1] - The public offering was oversubscribed over 100 times, and the international offering was 16.7 times oversubscribed, raising over HKD 1.8 billion [1] - The company is recognized as a key player in the small nucleic acid technology and pharmaceutical field in China, attracting participation from notable domestic and international investment institutions [1] Technology and Product Pipeline - Ribo Bio possesses a clinically validated liver-targeting GalNAc delivery technology, RiboGalSTAR™, which enables efficient and specific delivery of siRNA to liver cells [2] - The company has established a robust product pipeline with seven self-developed siRNA candidates in clinical stages, including RBD4059, the first siRNA drug targeting FXI for thrombotic diseases [2][3] - RBD4059 shows potential advantages in reducing bleeding risk while effectively combating thrombosis, with a long-acting profile that may extend dosing intervals to several months [2] Market Potential - The global small nucleic acid drug market is experiencing rapid growth, projected to increase from USD 2.7 billion in 2019 to USD 5.7 billion in 2024, and expected to reach USD 20.6 billion and USD 54.9 billion by 2029 and 2034, respectively [3] - Ribo Bio's pipeline aligns with significant unmet clinical needs, particularly in thrombotic diseases and hypertriglyceridemia, which are prevalent and have substantial patient populations [4] - RBD4059 and RBD5044 are positioned to address limitations of current therapies, with RBD5044 targeting high triglyceride levels showing potential to become a best-in-class therapy [4] Future Outlook - The successful listing on the Hong Kong Stock Exchange marks a new chapter for Ribo Bio, providing capital to support its development [5] - With a solid research foundation, differentiated product pipeline, and clear commercial strategy, Ribo Bio is poised to become an influential player in the global small nucleic acid therapy landscape, offering new treatment hopes for millions of patients worldwide [5]